Both, RevTM CEA-7B6 and RevTM CEA-IgG4-7B6 showed binding capability towards CEA+ cancer cells and RevCAR-E7B6 T-cells, in addition to induce specific lysis of CEA+ target cells accompanied by secretion of proinflammatory cytokines. The gene discussed is CEACAM5; the disease is cancer.